Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Merck & Co (NY: MRK)
88.75 USD  +0.08 (+0.09%)
Official Closing Price  /  Updated: 7:03 PM EST, Dec 5, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 7,889,000
Open 88.73
Bid (Size) 88.65 (3)
Ask (Size) 89.55 (3)
Prev. Close 88.67
Today's Range 87.97 - 88.79
52wk Range 70.89 - 88.79
Shares Outstanding 2,690,303,898
Dividend Yield 2.16%
Performance
YTD
+17.41%
+17.41%
1 Month
+7.03%
+7.03%
3 Month
+3.08%
+3.08%
6 Month
+8.98%
+8.98%
1 Year
+13.24%
+13.24%
Top News
More News
LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer
LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer Read More
from Business Wire News Releases
Merck Makes Newsweek’s Inaugural List of Most Responsible Companies
category most responsible companies , Awards, Ratings & Rankings , NYSE:MRK , and 4 more.
from 3BL Media: Corporate Social Responsibility, Energy and Health News
More News
Read More
UPDATE 2-Half a million Ebola vaccine doses to be stockpiled for emergency use
category companyNews
from Reuters: Company News
Trying Our Hand With Stocks At New Highs
category Futures , Stocks / Equities
from Blogs - TalkMarkets
UPDATE 1-Ebola vaccine doses to be stockpiled for emergency outbreak use
category companyNews
from Reuters: Company News
Ebola vaccine to be stockpiled for emergency use in outbreaks
category companyNews
from Reuters: Company News
Health Care & Merck Working A Bullish Breakouts
category Healthcare , ETFs , Stocks / Equities
from Blogs - TalkMarkets
Why Buy Junk? 7 Top Stocks Sparkle With Quality
from Investor's Business Daily
AstraZeneca/Merck PARP Inhibitor Approved in China for Ovarian Cancer
from ChinaBio® Today
AstraZeneca/Merck PARP Inhibitor Approved in China for Ovarian Cancer
from ChinaBio® Today
REFILE-AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.